Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: dot (14), spot (88), point (473), stop (1000)

Low-dose aspirin (150mg) in pregnancy - patient information

Description: This factsheet provides information about the use of low-dose aspirin (150mg) in pregnancy, including the benefits and risks.
Url: /Media/UHS-website-2019/Patientinformation/Pregnancyandbirth/Low-dose-aspirin-150mg-in-pregnancy-2239-PIL.pdf

Rectal spacer - patient information

Description: We have given you this factsheet because your doctor or nurse practitioner has recommended that you have radiotherapy treatment for prostate
Url: /Media/UHS-website-2019/Patientinformation/Cancercare/Rectal-spacer-3406-PIL.pdf

Tisacel - Cyclophosphamide (500) - Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY ALL – TISACEL– CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30) Regimen This regimen will o
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Tisacel-Cyclophosphamide-500-Fludarabine-30-Ver1.pdf

Carfilzomib Dexamethasone(40) Lenalidomide

Description: Chemotherapy Protocol MYELOMA Carfilzomib -Lenalidomide -Dexamethasone Regimen • Myeloma – Carfilzomib-Lenalidomide-Dexamethasone Indication • Carfi
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Carfilzomib-Dexamethasone40-Lenalidomide.pdf

Crizanlizumab Ver 1

Description: Chemotherapy Protocol Recurrent Vaso-Occlusive Crises in Sickle Cell Disease CRIZANLIZUMAB Regimen • Recurrent Vaso-Occlusive Crises in Sickle Cel
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sickle-Cell/Crizanlizumab-Ver-1.pdf

Papers Trust Board 27 May 2021

Description: Date Time Location Chair Agenda Trust Board – Open Session 27/05/2021 9:00 - 13:00 Microsoft Teams Peter Hollins 1 C
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2021-Trust-document/TB-papers/Papers-Trust-Board-27-May-2021.pdf

Atezolizumab-Carboplatin(AUC5)-Etoposide(IV/PO)

Description: Chemotherapy Protocol LUNG CANCER– SMALL CELL (SCLC) ATEZOLIZUMAB-CARBOPLATIN (AUC5)-ETOPOSIDE(IV/PO) Regimen  Lung - Atezolizumab-Carboplatin (AUC5)-Etopos
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Atezolizumab-CarboplatinAUC5-EtoposideIVPO.pdf

Carboplatin (AUC5) Retreat

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN Retreat (AUC5) Regimen • Ovary – Carboplatin (AUC5) Retreat Indication • Second line or subseque
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CarboplatinAUC5-Retreat.pdf

Joint protection techniques - patient information

Description: This factsheet provides information about joint protection techniques you may find useful, such as how to reduce pressure on your joints
Url: /Media/UHS-website-2019/Patientinformation/Muscles,jointsandbones/Joint-protection-techniques-3343-PIL.pdf

Transient ischemic attack (TIA) - patient information

Description: Transient ischemic attack (TIA) Information for patients You have been given this booklet because you have been refer
Url: /Media/UHS-website-2019/Patientinformation/Brain-and-spine/Transient-ischemic-attack-TIA-685-PIL.pdf

291 to 300 of 680

Previous … 28 29 30 31 32 … Next